Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.30 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL891079 | 0.91 | — | — | |
| SCHEMBL891439 | 0.86 | POLB (0.35) | KMT2AP2RY6P2RY14 | |
| SCHEMBL891653 | 0.83 | — | — | |
| SCHEMBL891700 | 0.83 | HSP90AA1 (0.31) | — | |
| SCHEMBL891962 | 0.79 | LMNA (0.38) | — | |
| SCHEMBL891694 | 0.79 | LMNA (0.38) | — | |
| SCHEMBL891674 | 0.78 | POLB (0.33) | — | |
| SCHEMBL891474 | 0.78 | POLB (0.33) | KMT2A | |
| SCHEMBL891166 | 0.77 | LMNA (0.40) | — | |
| SCHEMBL891602 | 0.77 | POLB (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120082645-A1 | 2'-C-METHYL-RIBOFURANOSYL CYTIDINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | XENOPORT, INC. (US) | 2012-04-05 | — | — | US | claimed |
| US-8058260-B2 | 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof | XENOPORT, INC. (US) | 2011-11-15 | — | — | US | claimed |
| US-20070270374-A1 | 2'-C-Methyl-Ribofuranosyl Cytidine Prodrugs, Pharmaceutical Compositions and Uses Thereof | XENOPORT, INC. | 2007-11-22 | — | — | US | claimed |
| US-20120082645-A1 | 2'-C-METHYL-RIBOFURANOSYL CYTIDINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | XENOPORT, INC. (US) | 2012-04-05 | — | — | US | disclosed |
| US-8058260-B2 | 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof | XENOPORT, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-20070270374-A1 | 2'-C-Methyl-Ribofuranosyl Cytidine Prodrugs, Pharmaceutical Compositions and Uses Thereof | XENOPORT, INC. | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120082645-A1 | 2'-C-METHYL-RIBOFURANOSYL CYTIDINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MTAP, NSUN2, CDA | KMT2A 990/4885P2RY6 305/4885P2RY14 1184/4885 |
| US-20070270374-A1 | 2'-C-Methyl-Ribofuranosyl Cytidine Prodrugs, Pharmaceutical Compositions and Uses Thereof | MTAP, NSUN2, PAICS | KMT2A 1114/4885P2RY6 289/4885P2RY14 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.